Physician profile
Saul Schaefer
NPI 1982686978
$110,032.27
in general payments reported to CMS, 2019-2025
21 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $16K · 2021: $9,652 · 2022: $17K · 2023: $7,489 · 2024: $11K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $3,278 · Travel and Lodging: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,037.50 |
| Food and Beverage | $3,277.87 |
| Travel and Lodging | $419.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75,614.53 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $30,445.99 | 2019-2021 | |
| Biotronik INC. | $986.01 | 2019-2024 | Acticor 7 Vr-T Dx, Amvia Edge |
| Shockwave Medical, INC | $613.08 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $370.21 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $362.71 | 2024-2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.23 | 2019-2022 | |
| Boston Scientific Corporation | $238.20 | 2019-2020 | |
| Heartflow, INC. | $203.45 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $178.96 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $175.44 | 2024 | Assure Wcd |
| Abbott Laboratories | $154.08 | 2021-2024 | Xience Skypoint, Dragonfly Opstar, Pressurewire |
| Amarin Pharma, INC. | $122.31 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $109.98 | 2019-2024 | Camzyos |
| Ge Healthcare | $51.42 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.27 | 2022-2024 | |
| Pfizer INC. | $26.12 | 2024 | |
| Abiomed | $20.21 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.38 | 2019 | |
| Recor Medical INC | $18.06 | 2024 | Paradise Renal Denervation System |
| Chiesi USA, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.